Ronald Harold Wilfred Cooper

Ronald Harold Wilfred Cooper, listed as chief executive, has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Albireo Pharma, Inc., Generation Bio Co. and enGene Holdings Inc. In total, 19 filings cover trades dated from 3 November 2016 to 9 February 2026.

Market trades split into 4 purchases (€96k) and 6 sales (€210k). Netting one side against the other leaves €114k of net selling. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 6 share grants and 1 option exercise.

A typical purchase (the median) is worth €20k. No cluster: in 4 purchases, no other insider of the company bought within 30 days.

The newest entry dates from 9 February 2026: a transaction, in Generation Bio Co. The last insider purchase was made public on 1 October 2024, 753 days ago. The median gap between a trade and its publication by SEC (Form 4) is 3 days. US insiders must file a Form 4 within two business days of a trade. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.